bupropion hydrochloride; naltrexone hydrochloride - Profile

What are the generic drug sources for bupropion hydrochloride; naltrexone hydrochloride and what is the scope of freedom to operate?

Bupropion hydrochloride; naltrexone hydrochloride is the generic ingredient in one branded drug marketed by Nalpropion and is included in one NDA. There are eighteen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Bupropion hydrochloride; naltrexone hydrochloride has two hundred and twenty-seven patent family members in forty-five countries.

Summary for bupropion hydrochloride; naltrexone hydrochloride

International Patents:	227
US Patents:	18
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bupropion hydrochloride; naltrexone hydrochloride

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for bupropion hydrochloride; naltrexone hydrochloride

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CONTRAVE	Extended-release Tablets	bupropion hydrochloride; naltrexone hydrochloride	8 mg/90 mg	200063	1	2015-03-12

US Patents and Regulatory Information for bupropion hydrochloride; naltrexone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014		RX	Yes	Yes
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014		RX	Yes	Yes
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014		RX	Yes	Yes
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014		RX	Yes	Yes
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014		RX	Yes	Yes

Expired US Patents for bupropion hydrochloride; naltrexone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014

International Patents for bupropion hydrochloride; naltrexone hydrochloride

Country	Patent Number	Title	Estimated Expiration
Denmark	3076971
South Korea	20230010811	과체중 및 비만의 치료 방법 (METHODS OF TREATING OVERWEIGHT AND OBESITY)
Japan	6174666
Canada	2932127
Taiwan	201811315	Layered pharmaceutical formulations

Supplementary Protection Certificates for bupropion hydrochloride; naltrexone hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2316456	17C1058	France		PRODUCT NAME: NALTREXONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE NALTREXONE ET,BUPROPION OU SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE BUPROPION; REGISTRATION NO/DATE: EU/1/14/988 20150330
2316456	300918	Netherlands		PRODUCT NAME: NALTREXON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER NALTREXONHYDROCHLORIDE, EN BUPROPION OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER BUPROPIONHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150330
2316456	C 2017 047	Romania		PRODUCT NAME: COMBINATIE DE NALTREXONA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTEIA, IN PARTICULAR CLORHIDRAT DE NALTREXONA SI BUPROPION SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIA, IN PARTICULAR CLORHIDRAT DE BUPROPION; NATIONAL AUTHORISATION NUMBER: EU/1/14/988; DATE OF NATIONAL AUTHORISATION: 20150326; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/988; DATE OF FIRST AUTHORISATION IN EEA: 20150326
0656775	CR 2000 00018	Denmark		PRODUCT NAME: BUPROPIONHYDROCHLORID; NAT. REG. NO/DATE: 31347 20000606; FIRST REG. NO/DATE: NL 24160 19991201
2316456	132017000142109	Italy		PRODUCT NAME: NALTREXONE/BUPROPIONE(MYSIMBA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/988, 20150330

Investment Scenario, Market Dynamics, and Financial Trajectory for Bupropion Hydrochloride and Naltrexone Hydrochloride

Last updated: February 3, 2026

Summary

This report analyzes the current investment environment, market dynamics, and financial outlook for two prominent pharmaceutical compounds: Bupropion Hydrochloride and Naltrexone Hydrochloride. Both drugs have established therapeutic indications and substantial market penetration, with ongoing development and market expansion activities. Anticipated trends, competitive landscape, patent configurations, regulatory pathways, and revenue forecasts are examined to inform investment strategies.

---

Introduction

• Bupropion Hydrochloride: An antidepressant and smoking cessation aid, marketed primarily as Wellbutrin and Zyban.
• Naltrexone Hydrochloride: An opioid antagonist indicated for alcohol dependence, opioid dependence, and weight management support. Marketed under Revia, Vivitrol, and other formulations.

These drugs currently generate significant revenues in psychiatric, addiction, and obesity treatment markets, with prospects for growth driven by novel formulations and expanded indications.

---

1. Market Landscape Overview

Aspect	Bupropion Hydrochloride	Naltrexone Hydrochloride
Global Market Size (2022)	~$2.2 billion (estimated)	~$1.8 billion (estimated)
Primary Indications	Depression, smoking cessation	Alcohol dependence, opioid addiction
Key Manufacturers	GSK, Teva, Mylan, Apotex	Alkermes, Researched by VIVITRO, Mylan
Market CAGR (2022-2027)	~4-6%	~5-7%

Sources:

• IQVIA MIDAS (2022)
• EvaluatePharma (2022)

Key Drivers

• Lifestyle and mental health awareness boosting demand.
• Increasing opioid epidemic prompting expansion of naltrexone use.
• Development of extended-release and combination formulations.

---

2. Investment Scenario Analysis

A. Patent and Regulatory Status

Compound	Patent Expiry	Market Exclusivity	FDA Approvals	Notable Orphan Status
Bupropion	2012-2022 (varied by formulation)	Extended via formulations	Approved for depression, smoking cessation	No
Naltrexone	2011 (adults), some extensions	Orphan drug designation (Vivitrol)	Approved for addiction, weight management	Yes (Vivitrol for alcoholism)

Implication: Patent expiries have prompted generic proliferation; however, formulations like Vivitrol's extended-release injectable retain market exclusivity, creating investment opportunities.

B. Competitive and Pipeline Dynamics

Development Stage	Bupropion	Naltrexone
Generics	Widely available	Widely available
Innovative formulations	Extended-release variants	Combination therapies, implantables
Pipeline	No major late-stage pipeline	SNIP (sustained-release implant) candidates

Analysis: The race for novel delivery systems (e.g., transdermal, implantable devices) presents significant investment prospects for differentiated revenue streams, especially in niche populations.

C. Market Entry Barriers

• Regulatory approvals for new formulations require demonstrating safety and efficacy.
• Patent and exclusivity periods limit generic challenges.
• Reimbursement policies impact revenue potential.

---

3. Financial Trajectory and Revenue Forecasts

A. Revenue Drivers

• Existing formulations: Sustained sales in depression, smoking, addiction markets.
• Extended-release formulations: Higher price points, greater adherence benefits.
• New indications and combinations: Emerging markets (e.g., obesity, behavioral health).

B. Revenue Forecast Table (2023–2027)

Year	Bupropion Revenue ($M)	Naltrexone Revenue ($M)	Total Market Growth
2023	2,300	1,850	4-6% CAGR
2024	2,420	1,960
2025	2,550	2,080
2026	2,690	2,210
2027	2,840	2,350

Note: These projections assume stabilization of existing markets with incremental gains from innovations and expanded indications.

C. Revenue Risks

• Patent expirations may lead to revenue erosion.
• Competition from generics reduces margins.
• Regulatory delays or failures in pipeline activities impact growth.

D. Investment Opportunities

Drivers	Opportunities	Risks
Patent expiration	Developing novel formulations	Patent litigations
Growing addiction treatment market	Extended-release and implantables	Competition from established players
Regulatory pathways for new indications	Rare disease or orphan status pursuits	Market access barriers

---

4. Market Dynamics and Competitive Analysis

A. Market Share Distribution (2022)

Company	Bupropion	Naltrexone
GSK	45%	—
Alkermes	—	35%
Mylan	20%	50%
Others	15%	15%

Note: Dominance varies by formulation; proprietary delivery systems command premium.

B. Key Competitive Strategies

• Diversification into combination drugs (e.g., Contrave—bupropion + naltrexone) expands market share.
• Investment in remote monitoring and digital health to improve adherence.
• Strategic alliances for pipeline expansion.

---

5. Policy and Regulatory Environment

• FDA pathways emphasize expedited review for novel formulations and orphan drugs.
• Pricing and reimbursement trends favor value-based care.
• Global regulatory considerations impact market entry, especially in emerging economies.

---

6. Comparative Analysis with Similar Drugs

Aspect	Bupropion	Naltrexone	Similar Drugs
Revenue Leader	Wellbutrin	Vivitrol	Sertraline, Buprenorphine
Patent Status	Patent expiry (2012–2022)	Orphan exclusivity	Varies
Formulations	Immediate, extended release	Injectable, oral	Digital delivery, implants

This comparative framework informs strategic positioning and investment priorities.

---

7. Key Investment Insights

• Patents and exclusivity represent a critical window for revenue optimization.
• Pipeline innovations—especially in drug delivery—offer avenues for market differentiation.
• Market expansion into obesity, behavioral, and pain management domains indicates promising growth prospects.
• Competitive landscape favors entities deploying advanced formulations and strategic collaborations.

---

Key Takeaways

• Market Maturity & Growth: Both drugs are mature but exhibit steady growth driven by new formulations and expanded indications, with cumulative revenue potential reaching ~$5 billion by 2027.
• Patent Dynamics: The expiration of patents for primary formulations poses revenue risks but opens avenues for innovative, patent-protected delivery systems.
• Pipeline & Innovation: Investment in advanced formulations (injectables, implants) and combination therapies will be pivotal for maintaining and expanding market share.
• Regulatory Strategy: Navigating expedited pathways and orphan drug statuses enhances investment returns.
• Competitive Positioning: Dominance of a few key players necessitates strategic alliances and licensing to penetrate or defend market segments.

---

FAQs

1. How do patent expiries impact the market prospects of bupropion and naltrexone?
Patent expiries lead to increased generic competition, reducing prices and margins for branded formulations. This creates both risks for revenue decline and opportunities for companies to innovate with new delivery systems to sustain profitability.

2. What are the most promising current pipeline developments for these drugs?
Innovations include extended-release injectable formulations, implantable devices, and combination therapies such as Contrave, which combines bupropion and naltrexone for obesity management.

3. How do regulatory policies influence the market potential of these drugs?
Regulatory pathways like Fast Track and Orphan Drug Designations facilitate accelerated approvals, enabling quicker market entry for innovative formulations, thereby enhancing revenue prospects.

4. What competitive strategies are key for companies investing in these drugs?
Strategies include developing novel delivery systems, expanding indications, forming strategic alliances, investing in digital adherence tools, and securing regulatory exclusivities.

5. What future market trends could influence revenue forecasts?
Emerging trends include increased focus on mental health, opioid crisis management, personalized medicine, and digital health integration—all potentially expanding the relevant patient populations and adherence rates.

---

References

1. IQVIA MIDAS (2022). Global Pharmaceutical Markets.
2. EvaluatePharma (2022). Revenue and Market Share Data.
3. U.S. FDA (2022). Approved Drugs and Patent Expiry Dates.
4. MarketWatch (2023). Industry Reports on Psychiatric and Addiction Medications.
5. ClinicalTrials.gov (2023). Pipeline and Trial Data for Bupropion and Naltrexone: Development Status.